Monthly Archives: July 2006

Biocon to launch new cancer drug

  • 7/7/2006
  • India
  • staff

A new cancer drug is on the way from Biocon. An announcement on these lines was made at the inauguration of Biocon Park, India’s largest integrated biotech hub. Dr APJ Abdul Kalam, the President of India inaugurated the park which comprises of an integrated cluster of research laboratories and manufacturing facilities laid out on a 90 acre expanse in Karnataka. Built with a total investment of Rs 650 crore, with further investments to follow, Biocon Park is the single largest capital investment made by Biocon in its 27-year history. Biocon Park is focused on exports of both biopharmaceutical products and research services.

The multi-product facilities will mainly cater to disease segments like cardiovascular, cholesterol reduction, immunosuppressant in organ transplantation, diabetes and cancer. On the occasion, the President dedicated India’s first indigenously developed monoclonal antibody, BIOMab EGFR (Epidermal Growth Factor Receptor) to the nation. This antibody is indicated for cancer and it works by binding only to cancer cell-specific antigens, and induce an immunological response against the targeted cancer cell. Although a large number of monoclonal antibodies have been introduced in the country, they are beyond the reach of a majority of cancer patients because of their prohibitive cost. Biocon joins the league of monoclonal antibody developers worldwide and aims to be a key player in this segment in the coming years. Biocon’s new cancer drug will also be effective in several other cancers that express EGFR, including colorectal, pancreatic, metastatic breast, non-small cell lung and brain cancers. BIOMAb EGFR is indicated for use in combination with radiation therapy or chemotherapy in patients with positive expression of EGFR in squamous cell carcinoma of head and neck cancer. In clinical trials, BIOMAb EGFR showed extensive proliferation inhibition activity in NSCLC, breast cancer, colorectal cancer, pancreatic cancer, and glioblastoma (brain tumours) as well.

July, 2006|Archive|

Addition of Taxotere® to Chemotherapy Helps Preserve Function of Larynx

  • 7/7/2006
  • Iowa City, IA
  • staff
  • Cancer

According to results presented at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO), the addition of Taxotere® (docetaxel) to Platinol® (cisplatin) and 5-fluorouracil improves the rate of preservation of the larynx (voice box) in patients with advanced head and neck cancers.

Approximately 40,000 people in the United States are diagnosed with head and neck cancer every year. Cancers of the head and neck include several types of cancers affecting different areas of the head and/or neck. In 2005 the American Cancer Society estimated that 11,000 people would die from head and neck cancer.

Laryngeal cancer refers to cancer originating in the larynx, which is located within the throat. Hypopharyngeal cancer refers to cancer that originating in the bottom of the throat. Advanced head and neck cancer refers to cancer that spreads from its site of origin to other sites in the body. Standard treatment for advanced head and neck cancer often includes the use of several chemotherapy agents, the targeted agent Erbitux® (cetuximab), radiation therapy and/or surgery.

Often, the surgical removal of laryngeal or hypopharyngeal cancer leaves patients with severe disfigurement, as well as impairment in quality of life issues. Due to the side effects associated with surgery, physicians may first treat the cancer so that it shrinks prior to surgery. The goal of treatment of advanced head and neck cancer is to preserve as much function and cosmetics as possible, while providing optimal long-term survival.

Researchers affiliated with the French GORTEC (Radiotherapy Oncology Group for Head and Neck) 2000-01 trial recently evaluated the addition of the chemotherapy agent Taxotere to a standard chemotherapy combination including Platinol and 5-FU. This trial included 220 patients with advanced laryngeal or hypopharyngeal cancers who were treated with either Taxotere/Platinol/5-FU (TPF) or Platinol/5-FU (PF) as initial therapy and were directly compared.

– Overall anti-cancer responses were achieved in 83% of patients treated with TPF, compared with 61% for those treated with PF.

– At 3 years, 73% of patients treated with TPF were able to preserve the function of their larynx, compared with only 63% in the group treated with PF.

– There were no notable differences in side effects between the two groups of patients.

– There was a trend toward improved survival among patients treated with TPF.

The researchers concluded that the addition of Taxotere to PF improves the rate at which the larynx can be preserved without affecting survival among patients with advanced laryngeal or hypopharyngeal cancers. Patients diagnosed with head and neck cancer may wish to speak with their physician regarding their individual risks and benefits of treatment with Taxotere.

Calais G, Pointreau M, Alfonsi C, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Journal of Clinical Oncology . 2006;24: abstract # 5506.

July, 2006|Archive|

Christie Hospital Researches Power of Honey

  • 7/6/2006
  • Manchester, Egland
  • Robbie MacDonald
  • South Manchester Reporter (

The ancient Egyptians believed it was a cure-all. Scots mix it with whisky for medicinal ‘hot toddies’. And Winnie the Pooh loved the stuff.

Now in south Manchester, honey is being used to protect mouth and throat cancer patients from the MRSA superbug and other infections which are resistant to anti-biotics.

In a worldwide first, the Christie Hospital is researching the powers of New Zealand honey to help mouth and throat cancer patients’ recover after surgery.

Some of honey’s healing powers have been known for many years.

For example, it can help scars and wounds, or be put on dressings. Nurses at Manchester Royal Infirmary have been using special honey coated dressings for the last two months.

But the Christie work is unique.

Survival rates for people suffering from throat and mouth cancer have improved over the last 15 years, thanks to doctors more effectively combining surgery with chemotherapy and radiotherapy treatments.

An unfortunate side-effect, however is a condition called mucositis, which is an inflammation and infection of the lining tissue inside patients’ mouths and throats.

The ongoing study is looking at whether manuka honey from New Zealand can reduce this inflammation and prevent infection.

Sixty patients there have taken part in the study so far – and final results are expected in about 12 months.

Specialist Dr Nick Slevin is leading the study and said: “Manuka honey has special anti-inflammatory and anti-infection properties, and is believed to reduce the likelihood of MRSA infection. We’ve had 400 kilograms of honey shipped here from New Zealand.”

Bees produce the honey from the manuka bush. Small jars can cost around £12 in health shops but Christie is buying in bulk.

The hospital’s head and neck cancer team is undertaking many important studies into treatment and care. But the work is totally reliant on donations for the research.

Dr Slevin, who lives in Didsbury, added: “This study has been generously funded by local people and patients, and we are extremely grateful to them.”

July, 2006|Archive|

Hutchison Chi-Med given go-ahead to broaden scope of cancer drug trial

  • 7/6/2006
  • London, England
  • staff

Recently-listed Hutchison China Meditech Ltd said US medicine regulators have given it permission to broaden the scope of the first clinical trials of its lead experimental cancer drug.

HMPL-002 is a botanical extract under development as an orally administered treatment of head and neck cancer and non-small cell lung cancer in patients undergoing radiotherapy.

The phase I/II trials can now be widened to include the much larger population undergoing concurrent platinum-based chemoradiotherapy, which is now considered the standard treatment for most locally advanced head and neck cancers.

Chief executive Christian Hogg described the decision as ‘good news’.

‘Widening the universe among which we can conduct clinical trials will make it easier and speedier to recruit trial patients. More fundamentally, it broadens the future market potential for this important drug candidate.’

July, 2006|Archive|

Health First-Oral cancer

  • 7/6/2006
  • Flint, MI
  • Leslie LoBue

One person dies of oral cancer every hour. But that wouldn’t be the case if more people caught the cancer early.

Right now, half of the people diagnosed with oral cancer die- with early detection it is 90-percent survivable.

His speech is impaired and some of his neck is gone. He can’t swallow without water. All because no one noticed a lesion in Brian Hill’s mouth until it was late stage cancer.

“I ate healthy. I never smoked a day in my life. I’m going, ‘How could this be happening to me?'”

It may not have happened if the discovery made in a UCLA lab had come six years earlier. As it turns out, your saliva contains better bio markers than blood for detecting oral cancer.

“We don’t have to stick a needle into someone’s vein or give someone a cup and have them go to the bathroom, which could be embarrassing. And it’s non-painful,” said Dr. David Wong, DMD.

The test is simple. You spit into a tube that’s taken to the lab and tested for bio markers that signal cancer. It’s similar to the PSA test for prostate cancer, but it’s nearly 20 percent more accurate.

“Within 24 hours, it will be known if Mrs. Jones, you are at risk for oral cancer in your mouth, or you have a clean bill of health,” Wong said.

If found early, treatment can be as simple as removing a precancerous lesion with a laser.

“In all cancers, I don’t care which you pick, where we’ve seen a drop in the death rate, it hasn’t been through some miracle drug. It’s always been early detection,” Hill said.

While Brian is now cancer-free, he and his wife Ingrid know the pain of catching this disease too late. They hope the test will save others from the same fate.

The saliva test is about 82 percent accurate at detecting oral cancer. Wong says it should be available through your doctor or dentist within about two years so.

He thinks it may eventually be used to screen for breast and pancreatic cancer and also Alzheimer’s disease.

July, 2006|Archive|

Vitamins’ use in stopping cancer debated

  • 7/5/2006
  • Atlanta, GA
  • Mike Stobbe

Your parents may still tell you to take your vitamins, but a cancer doctor might be less enthusiastic. A recent study that found calcium and vitamin D supplements don’t reduce the odds of developing breast cancer is the latest to deflate the cancer-prevention claims of some vitamin proponents.

A federal science panel last month had concluded there is no evidence for recommending certain vitamin supplements for cancer prevention. Even the Council for Responsible Nutrition, a supplement trade association, won’t say vitamins prevent cancer.

“There is no vitamin or mineral supplement proven to reduce the risk of cancer,” said Eric Jacobs, a senior epidemiologist and vitamin specialist with the American Cancer Society.

However, many doctors continue to recommend daily multivitamins for general health. And some experts say certain supplements may yet prove to be a help in the fight against cancer — once scientists can work out the right amounts and better ways to study their effects.

“I do think there is a fundamental issue of finding the optimal dose of essential nutrients,” said Dr. Walter Willett, a professor of epidemiology and nutrition at the Harvard School of Public Health.

Experts say more research is needed.

“More than half of Americans are taking dietary supplements — mostly multivitamins — but scientists aren’t certain about their benefit,” said Dr. J. Michael McGinnis, who chaired the National Institutes of Health panel that critiqued supplemental vitamins.

“For something used so widely, at such expense, among Americans, there is simply a need for much better information,” he said.

Scientists once suspected vitamin E and beta-carotene prevented lung cancer after a study showed people who took supplements appeared to have lower cancer incidence.

But a larger, more scientifically rigorous study found 50 milligrams a day of alpha-tocopherol, a form of vitamin E, had no effect on lung cancer incidence. And 20 milligrams of beta-carotene, a precursor of vitamin A, actually increased lung cancer incidence in smokers by 18 percent. Health officials now warn smokers not to take beta-carotene supplements.

Studies also have found that beta-carotene has no impact on the incidence of lung cancer in non-smokers, or prostate or breast cancer. And research has found vitamin B2 and niacin had no impact on the occurrence of cancers, and selenium did not decrease skin cancer in people with a history of that disease.

More recently, a study published in April in the Journal of the National Cancer Institute concluded that a low-dose vitamin A derivative did not prevent head and neck tumors. Earlier research had suggested that higher doses of the derivative cut occurrence of subsequent tumors. But those higher doses caused severe cracking of the lips, eyelid inflammation and other problems, researchers said.

A study of about 36,000 post-menopausal women released this month found calcium and vitamin D supplements didn’t cut the odds of developing breast cancer.

Willett, the Harvard expert, faulted the study led by Dr. Rowan Chlebowski of Harbor-UCLA Medical Center in Los Angeles and said a different dose of vitamin D may be needed to show an effect. He also said it’s possible vitamins and supplements reduce cancer risk at one stage of life, but not another, as a previous Canadian study suggested.

Much of the research into potential cancer-fighting powers of vitamins and other supplements have been observational studies, said Andrew Shao, the Council for Responsible Nutrition’s vice president for scientific and regulatory affairs.

But the gold standard is large, case-controlled trials involving elaborate precautions to isolate cause and effect and prevent biased results. Such studies are expensive and take many years to complete.

Also, if dosage is a key and researchers select the wrong dosage, such a study may find no benefit but miss that the vitamins reduce cancer risks at a different dose, he said.

Shao and others say there have been promising results regarding selenium’s value against cancers other than skin cancer, and that continued work on folate and vitamins D and E also seems rewarding.

Meanwhile, patients are making their own decisions.

Lisa McRae, a 39-year-old real estate agent in suburban Atlanta, began taking supplements after she was diagnosed with breast cancer in December.

She and her mother read dozens of books discussing the value of diet and nutrients in combating chronic diseases. Staff at a hospital referred her to an acupuncturist, who recommended a Chinese herbal mix and seven other supplements.

McRae believes they can help her fight cancer, both now in the future.

“I think more people need to realize there are several ways to combat this disease,” she said.

July, 2006|Archive|

Concomitant Analysis of Salivary Tumor Markers—A New Diagnostic Tool for Oral Cancer

  • 7/4/2006
  • Israel
  • Rafael Nagler et al.
  • Clinical Cancer Research Vol. 12, 3979-3984, July 1, 2006

Oral squamous cell carcinoma (OSCC) is a common human malignancy. Circulatory epithelial tumor markers were previously investigated in the serum of OSCC patients but almost never in their saliva, in spite of the fact that there is a direct contact between the saliva and the oral cancer lesion. The purpose of the current study was to examine tumor markers in the saliva of OSCC patients.

Experimental Design:
We measured the concentrations of the six most studied epithelial serum circulatory tumor markers in the saliva of OSCC (tongue) patients.

Significant increases (of 400%) in salivary concentrations of Cyfra 21-1, tissue polypeptide antigen, and CA125 were shown. Salivary concentrations of CA19-9, SCC, and carcinoembryonic antigen were increased without statistical significance. A concurrent analysis of the three significantly increased markers revealed sensitivity, specificity, and negative and positive predictive values of 71%, 75%, 71%, and 75%, respectively.

The increase reported in salivary tumor markers may be used as a diagnostic tool, especially when a concurrent analysis for significantly increased markers is done. Salivary testing is noninvasive, making it an attractive, effective alternative to serum testing, and the possibility of developing home testing kits would further facilitate it as a diagnostic aid, enabling patients to monitor their own health at home and is important for those who live far from their treatment centers and especially for those at risk of developing OSCC.

Rafael Nagler1, Gideon Bahar2, Thomas Shpitzer2 and Raphael Feinmesser2

Authors’ affiliations:
1 Department of Oral and Maxillofacial Surgical and Oral Biochemistry Laboratory, Rambam Medical Center and Rappaport Faculty of Medicine, Israel Institute of Technology-Technion, Haifa, Israel and
2 Department of Otorhinolaryngology, Rabin Medical Center, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

July, 2006|Archive|

Buckyballs Boost Antibody’s Chemotherapy Payload

  • 7/4/2006
  • Houston, TX
  • staff

Nanoparticles could deliver multi-drug therapy to tumors

In the ongoing search for better ways to target anticancer drugs to kill tumors without making people sick, researchers find that nanoparticles called buckyballs might be used to significantly boost the payload of drugs carried by tumor-targeting antibodies.

In the ongoing search for better ways to target anticancer drugs to kill tumors without making people sick, researchers find that nanoparticles called buckyballs might be used to significantly boost the payload of drugs carried by tumor-targeting antibodies.

In research due to appear in an upcoming issue of the journal Chemical Communications, scientists at Rice University and The University of Texas M. D. Anderson Cancer Center describe a method for creating a new class of anti-cancer compounds that contain both tumor-targeting antibodies and nanoparticles called buckyballs. Buckyballs are soccer ball-shaped molecules of pure carbon that can each be loaded with several molecules of anticancer drugs like Taxol®.

In the new research, the scientists found they could load as many as 40 buckyballs into a single skin-cancer antibody called ZME-018. Antibodies are large proteins created by the immune system to target and attack diseased or invading cells.

Previous work at M. D. Anderson has shown that ZME-018 can be used to deliver drugs directly into melanoma tumors, and work at Rice has shown that Taxol can be chemically attached to a buckyball.

“The idea that we can potentially carry more than one Taxol per buckyball is exciting, but the real advantage of fullerene immunotherapy over other targeted therapeutic agents is likely to be the buckyball’s potential to carry multiple drug payloads, such as Taxol plus other chemotherapeutic drugs,” said Rice’s Lon Wilson, professor of chemistry. “Cancer cells can become drug resistant, and we hope to cut down on the possibility of their escaping treatment by attacking them with more than one kind of drug at a time.”

Researchers have long dreamed of using antibodies like ZME-018 to better target chemotherapy drugs like Taxol, and M. D. Anderson’s Michael G. Rosenblum, Ph.D., professor in the Department of Experimental Therapeutics and Chief of the Immunopharmacology and Targeted Therapy Laboratory, has conducted some of the pioneering work in this field.

“This is an exciting opportunity to apply novel materials such as fullerenes to generate targeted therapeutics with unique properties,” Rosenblum said. “If successful, this could usher in a new class of agents for therapy not only for cancer, but for other diseases as well.”

While it’s possible to attach drug molecules directly to antibodies, Wilson said scientists haven’t been able to attach more than a handful of drug molecules to an antibody without significantly changing its targeting ability. That happens, in large part, because the chemical bonds that are used to attach the drugs — strong, covalent bonds — tend to block the targeting centers on the antibody’s surface. If an antibody is modified with too many covalent bonds, the chemical changes will destroy its ability to recognize the cancer it was intended to attack.

Wilson said the team from Rice and M. D. Anderson had planned to overcome this limitation by attaching multiple molecules of Taxol to each buckyball, which would then be covalently connected to the antibodies. To the team’s surprise, many more buckyballs than expected attached themselves to the antibody. Moreover, no covalent bonds were required, so the increased payload did not significantly change the targeting ability of the antibody.

Wilson said certain binding sites on the antibody are hydrophobic (water repelling), and the team believes that these hydrophobic sites attract the hydrophobic buckyballs in large numbers so multiple drugs can be loaded into a single antibody in a spontaneous manner to give the antibody-drug agent more “bang for the buck.”

“The use of these nanomaterials solves some intractable problems in targeted therapy and additionally demonstrates the increasing value of the team science approach bridging different disciplines to uniquely address existing problems,” Rosenblum said.

Rice University

July, 2006|Archive|

Attacking Cancer’s Sweet Tooth Is Effective Strategy Against Tumors

  • 7/4/2006
  • Cambridge,MA
  • staff

An ancient avenue for producing cellular energy, the glycolytic pathway, could provide a surprisingly rich target for anti-cancer therapies. A team of Harvard Medical School (HMS) researchers knocked down one of the pathway’s enzymes, LDHA, in a variety of fast-growing breast cancer cells, effectively shutting down glycolysis, and implanted the cells in mice. Control animals carrying tumor cells with an intact glycolytic pathway did not survive beyond 10 weeks. In striking contrast, only two of the LDHA-deficient mice died, one at 16 weeks, another at just over 18 weeks. Eighty percent of the mice outlived the four month experiment. The findings by Valeria Fantin, Julie St-Pierre, and Philip Leder appear in the June Cancer Cell.

“This is an exciting contribution that reveals a surprising Achilles heel in cancer cells. It also adds to our sense of opportunity for new avenues of cancer therapeutics,” said Stuart Schrieber, Morris Loeb professor and chair of the Department of Chemistry and Chemical Biology at Harvard University.

As a tumor grows, cells crowd one another and may be cut off from oxygen-carrying blood vessels–a distinct disadvantage since most cells require oxygen to produce the bulk of their energy-storing adenosine triphosphate (ATP). In the 1920s, Otto Warburg proposed that some cancer cells evolved the ability to switch over to an ancient, oxygen-free route, the glycolytic pathway. What is more, they continue to use this pathway even when access to oxygen is restored. Though the so-called Warburg effect has since been confirmed, the role played by glycolysis in cancer has been largely ignored. Few have attempted to attack specific points along the glycolytic pathway to gain a therapeutic effect.

“LDHA could be one weak point that we could attack but maybe, if we understand exactly all the steps involved, we could devise alternative strategies to attack the same pathway,” said Fantin, who was an HMS research fellow in genetics when the study was performed. She is currently a research scientist at Merck & Co.

What may excite the growing band of researchers who are studying the Warburg effect, and cancer metabolism more generally, is the way the study resolves a long-standing debate about how and why cells switch to glycolysis in the first place. Warburg speculated that cancer cells change over to glycolysis, which occurs in the cytoplasm, because the mitochondria, where oxygen-dependent ATP synthesis occurs, are defective. But the mitochondria of cancer cells appear to be mostly intact, which led many researchers to minimize the importance of the glycolytic switch.

The mitochondria do display an intriguing difference, however. Normally, mitochondria turn glucose into ATP through the oxygen-dependent process of oxidative phosphorylation (OXPHOS). This results in the expulsion of protons, which lowers the mitochondria’s membrane potential. Curiously, the mitochondria of cancer cells exhibit a high membrane potential. Researchers suspected that was because the cells have switched to an alternative means of producing ATP, namely glycolysis, but it was not clear if the glycolytic and mitochondrial pathways were connected in this fashion.

It appears the two pathways are reciprocally linked. Fantin and her colleagues found that by shutting down the glycolytic pathway (through the knock down of LDHA), they could lower the mitochondrial membrane potential of tumor cells. What is more, oxygen consumption increased in the knockdown cells, suggesting they were reverting to the mitochondrial OXPHOS pathwayÑa kind of Warburg effect in reverse.

“The findings provide us with an insight into a mechanism that had been suspected in the last six or seven decades,” said Leder, John Emory Andrus professor and chair of the Department of Genetics at HMS. Knocking out the glycolytic pathway could deliver a big blow to tumor cells.

“LDHA could be one weak point that we could attack but maybe, if we understand exactly all the steps involved, we could devise alternative strategies to attack the same pathway,” Fantin said.

What makes the prospect of anti-glycolytic therapies even more attractive is their potential safety.

Healthy cells meet 90 percent of their energy needs through OXPHOS. People who lack the LDHA enzyme appear to function normally though they cannot be pushed toward anaerobic exercise.

“They have muscle destruction because they lack an alternative route for producing energy,” Fantin said. It is not clear whether they have a lower indidence of cancer.

Also appealing is the idea of combining anti-glycolytic therapies with anti-angiogenic ones.

“If you have a molecule that is very stable you could think about delivering it first, obliterating the glycolytic pathway,” said Fantin. Angiogenesis inhibitors would wipe out blood vessels and the oxygen supply with it, leaving the cells with no way to cope. “There is definite potential to combining these things,” she said

Harvard Medical School

July, 2006|Archive|

Blue Light Shines Spotlight on Oral Cancer

  • 7/4/2006
  • Vancouver, British Columbia, Canada
  • Scott Fields

A hand-held light may soon help dentists and physicians find oral cancer faster and more reliably.

That’s important because in America alone each year 30,000 people are diagnosed with oral cancer, and only half of them will survive more than five years, according to the National Institute of Dental and Craniofacial Research.

And people who do survive oral cancer may do so at the cost of painful and disfiguring surgery, as chunks of tongue, jaw or palate are carved from the patient’s mouth.

The problem, says Miriam Rosin, a cancer biologist at the British Columbia Cancer Research Center in Vancouver, British Columbia, Canada, is not only that dentists and general practitioners don’t do frequent enough inspections, but that when they do, they usually inspect the mouth under ordinary light.

Ordinary light doesn’t highlight what has turned out to be a reliable indicator of some cells’ health: their natural fluorescence.

In the right environment, specifically under a specialized blue light, cells can flash their condition like a lighthouse warning of a submerged reef.

This new device, called a Visually Enhanced Lesion Scope, or “VELScope,” (combined with program of regular oral checkups, Rosin cautions) could reveal early evidence of the fast-spreading disease, which is most common in smokers and heavy drinkers.

Used correctly, the device can spotlight cells that have turned to the dark side, literally, as well as those that are teetering on becoming cancerous.

“You shine a blue light on the tissue and it excites fluorophores in the tissue to release fluorescence of a specific wavelength,” Rosin explains. “It looks green, because we have filters in the system, and what we’re looking for is the loss of that green color.”

When viewed through an eyepiece attached to the light source, healthy cells shine pale green. But abnormal, potentially cancerous “dysplastic” cells look dark green to black.

Dark cells don’t necessarily equal cancerous cells, she says, but a biopsy would be a wise next step.

In fact, when Rosin’s group shined the VELScope into 44 mouths, healthy cells were correctly distinguished from abnormal cells for 43 of the patients.

In these tests, the scientists were able to detect all of the patients who did not have abnormal cells in a specific test site and were able to detect cancerous conditions with 98-percent confidence.

This research was published in the March/April issue of the Journal of Biomedical Optics. Other scientists are developing similar devices to hunt down cervical cancer and lung cancer.

July, 2006|Archive|